# Handoff: THREATNEXUS-FUNCTIONAL-CLOSURE

- From: claude
- Branch: `docs/tnx-functional-closure`
- Worktree: `F:\AI-Worktrees\ThreatNeXus\closure`
- Base / merged main: `origin/main` @ `eb19f4e` (merge of PR #27, TNX-P10C5)
- Updated: 2026-08-18
- Status: **core_functionally_closed** — Tier N/A (reconciliation, not an engineering ticket).

## CORE FUNCTIONAL STATUS: CLOSED

The Phase-10 engineering sequence (10A → 10B → 10C1 → 10C2 → 10C3 → 10C4 → 10C5) is complete and
merged. No P0/P1 functional blocker exists at the current merged tip. **Begin optional endgame on
separate explicit authorization; this run started none of it.**

## What was actually checked (reconciliation, not rediscovery)

- **Merge confirmed by Git, not assumed:** `git merge-base --is-ancestor` proves the TNX-P10C5
  branch is a real ancestor of `origin/main`.
- **Merged-head regression evidence — the cheapest, strongest signal available:** every merge-to-main
  CI run from PR #23 (TNX-P10C1) through PR #27 (TNX-P10C5) completed successfully
  (`gh run list --branch main`). This directly answers "did composing these five tickets together
  break anything" without re-running any local suite.
- **Default-off / provider-safety invariants, grep-verified at the merged tip** (not trusted from
  memory): `AI_ENABLED`, `ENRICHMENT_WORKER_ENABLED`, `AUTO_ENRICHMENT_ENABLED` all default `false` in
  both `backend/src/config/env.js` and `docker-compose.yml`; `IOC_ENRICHMENT_PROVIDER` defaults
  `mock` in both. No unintended live/provider default is enabled.
- **Core data model present:** `User`, `AuditLog`, `Case`, `Notification`, `Finding`, `RiskScore`,
  `GreyNoiseEnrichment` all confirmed in `backend/prisma/schema.prisma` at the merged tip.
- **Core frontend routes present:** Dashboard, Findings, FindingDetail, Cases, CaseDetail,
  Notifications, NotificationDetail, Organizations, Settings, Profile, Analytics, AttackNavigator,
  Login — the full route set the product's core journeys require.
- **TNX-P10C5's own closure evidence stands** (recorded earlier this session, not repeated here):
  177/177 provider suites, 56/56 legacy-route integration, 96/96 inertness/evidence/security, 34/34
  real-Postgres Phase-10A-2 execution, 3640/3642 full backend suite, zero schema/migration diff, zero
  live provider contact, one `security-reviewer` pass CLEAR (0 P0/P1).
- **Stale planning artifacts identified and correctly NOT reopened:** `docs/ai/TASKS.md` stops
  tracking at Phase 6.3; `../ThreatNeXus-Planning/planning/NEXT_STEPS.md` still says "no
  implementation work has started"; `BUILD_PLAN.md` only defines Phases 0–7. All three predate the
  STATE.yaml/HANDOFF.md-per-ticket execution record this project actually used from Phase 0 onward.
  Historical wording, not a functional gap — per this run's own explicit instruction not to reopen
  work merely because an old doc disagrees.

## What was updated (minimal, truthful, not a documentation redesign)

`README.md`'s "Current status" table was frozen at Phase 9B.1. Added one row each for 10A, 10B,
10C1–10C3 (grouped), 10C4, and 10C5, corrected the heading and the Roadmap anchor/claim to match, and
added one new Roadmap bullet recording the still-pending external report dependency (below). This is
the "README-facing project status" correction this closure run was asked to make — the *professional*
documentation/diagram finalization pass remains deferred to optional endgame phase C.

## External dependency — recorded truthfully, not fabricated or marked complete

**The expected Rapid7/Sonar-style Open Data (or comparable Shadowserver-style Accessible-RDP)
report/access response has NOT yet been received.** This is an external data/access dependency, not
an application defect: the synthetic dataset already exercises the full ingest → triage → case →
notification → closure path today, and nothing in the ingestion contract depends on receiving the
external report. If it continues to be unavailable, a legitimate alternate demo dataset may be
substituted for demonstration purposes only, **provided its provenance is recorded truthfully** rather
than presented as the original source. Not researched, not downloaded, not substituted this run.

## Deferred / non-blocking (correctly not converted into new tickets)

- The four legacy synchronous provider routes remain an off-ledger, credential-armed contact path —
  now body-size-bounded by 10C-5, still not retired/hardened. Unowned; carried forward, not reopened.
- 10C-5's own disclosed residuals (bounding beyond the shared 2 MiB limit for large/variable
  responses; `lookupWithBound`'s outer `Promise.race` still doesn't thread a cancellation signal)
  remain required only before unattended/production/batch>1 enablement — not before functional
  closure of the current bounded local/demo deployment model.
- Whether the CI job for `phase10c3UsageService.test.js` sets `TEST_DATABASE_URL` (carried forward
  from 10C-3, not re-checked this run — out of scope for a merged-head regression pass).

## Optional endgame — approved, recorded, NOT started

Three bounded activities remain, each requiring separate explicit authorization before starting, one
at a time:

**A. Security / pentest pass — if time.** Read-only audit/pentest → prioritized evidence → fix P0/P1
and only the highest-value P2 if time → one targeted re-test → STOP. No endless security loop.

**B. Deep frontend/UI-UX audit + one polish pass.** One rendered, page-by-page audit first (login,
dashboard, findings, finding detail, cases, settings, navigation, loading/error/empty states,
mobile/responsive, accessibility, visual cohesion, motion opportunities). Route each recommended
improvement to the right capability rather than reaching for tools because they exist. Implement one
approved bounded set, one browser QA pass, STOP. No second polish loop.

**C. Professional final documentation.** After (A)/(B) settle the product surface: README, overview,
architecture, data-flow diagrams, screenshots, security model, deployment/setup, demo workflow,
external-data provenance (including the Rapid7/Sonar dependency above), limitations. No AI
watermarks, no fabricated claims.

## Next action

Wait for explicit authorization to begin (A), (B), or (C). Do not invent a Phase 11. Do not reopen
10A–10C5 without genuine new P0/P1 evidence.
